AAD

AMERICAN ACADEMY OF DERMATOLOGY SURVEY SHOWS GEN Z ADULTS AT RISK FOR SKIN CANCER DUE TO INCREASING RATES OF TANNING AND BURNING

Retrieved on: 
tisdag, maj 14, 2024
Patient, American Academy, Generation, FAAD, Risk, SPF, Statistics, Tanning, Skin cancer, Gen, Skin, Sand, UV, Bleeding, Generation Z, Ageing, Fear, MD, Melanoma, Sunburn, Beauty, AAD, Perspiration, Swimming, Bed, Water, Habit, Cosmetics

ROSEMONT, Ill., May 14, 2024 /PRNewswire/ -- A new survey from the American Academy of Dermatology revealed that Generation Z adults, ages 18-25, are at risk for skin cancer due to increasing rates of tanning and burning. To encourage safe sun habits, the AAD is shining a spotlight on the ways that people can protect themselves from the most common and one of the most preventable types of cancer—skin cancer—this May for Skin Cancer Awareness Month.

Key Points: 
  • ROSEMONT, Ill., May 14, 2024 /PRNewswire/ -- A new survey from the American Academy of Dermatology revealed that Generation Z adults, ages 18-25, are at risk for skin cancer due to increasing rates of tanning and burning.
  • According to the national survey of over 1,000 U.S. adults, 52% of Gen Z adults were unaware of one or more sunburn risks, such as increased risk of developing skin cancer or premature skin aging.
  • Twenty-eight percent of Gen Z survey respondents said getting a tan was more important to them than preventing skin cancer, with 70% reporting tanned or darker skin in 2023.
  • As this damage builds, you speed up the aging of your skin and increase your risk for all types of skin cancer, including melanoma, the deadliest form of skin cancer.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
American Academy, Ulcerative colitis, BDCA2, American Association of Immunologists, CDAI, American Academy of Dermatology, PD-1, IND, Week, AAI, Therapy, Patient, Graft-versus-host disease, Rheumatoid arthritis, AAD, Atopic dermatitis, BTLA, SAN, UC, Pharmaceutical industry

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
tisdag, maj 7, 2024
Komodo, Psoriatic arthritis, VELA, FDA, American Academy, Porokeratosis, Psoriasis, HS, Skin, Rheumatology, MDA, Research, Partnership, Conference, PPP, MIRA, Joint, Bimekizumab, Patient, EMA, AAD, Inflammation, PASI, Moonlake, Dermatology, ARGO, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

AMERICAN ACADEMY OF DERMATOLOGY SURVEY SHOWS OUTDOOR WORKERS MORE AT RISK FOR SKIN CANCER THAN AVERAGE AMERICANS

Retrieved on: 
tisdag, maj 7, 2024
Moles, UPF, American Academy, University, Cancer, Perspiration, Blister, Carcinoma, Risk, Skin, Burn, American Academy of Dermatology, Hand, MD, Dermatology, Sunburn, Skin cancer, Life, Tanning, AAD, Melanoma, SPF, Human, Swimming, Emergency medical services, UV, Clothing, Cosmetics

ROSEMONT, Ill., May 7, 2024 /PRNewswire/ -- A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that outdoor workers – like those who work in construction, landscaping, emergency medical services, and postal delivery – are far more likely to get sunburned and tanned, putting themselves at increased risk for skin cancer, compared to the average American. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone – and especially those who work outdoors – to practice safe sun to protect themselves from the sun's harmful rays and reduce their risk of developing skin cancer.

Key Points: 
  • According to the survey, half of outdoor workers were sunburned in 2023, compared to 36 percent reported by the general American population.
  • One in 10 outdoor workers had sunburns severe enough to cause blisters, a rate double that of the general population.
  • And nearly 80 percent of outdoor workers got a tan or darker skin as a result of sun exposure, compared to 67 percent of Americans overall.
  • Tanning and unprotected sun exposure are major risk factors for skin cancer, the most common form of cancer in the United States and one of the most preventable types of cancer.

DermCare Management Expands with New Partnerships in the Greater Dallas Area

Retrieved on: 
måndag, maj 6, 2024
American Medical Association, Dermatology, AAD, Health, Continuing medical education, Knowledge, Veterinary medicine

DermCare Management welcomes Dr. Christine Brown Dermatology and Dr. Kim Dermatology to the DermCare family of Texas dermatology practices.

Key Points: 
  • DermCare Management welcomes Dr. Christine Brown Dermatology and Dr. Kim Dermatology to the DermCare family of Texas dermatology practices.
  • Joining Dermatology Treatment and Research Center in Dallas, TX, and Stone Oak Dermatology in San Antonio, TX,  these two newly acquired practices further cement DermCare Management's commitment to supporting exceptional patient care in the Lone Star state.
  • Both Dr. Christine Brown and Dr. Kim Werner Billet bring a wealth of knowledge and specialized experience to DermCare Management.
  • We invite any private practice dermatologist looking to leverage our business management expertise and solidify their presence in their community to connect with DermCare Management to learn about our personalized support services and partnerships."

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology

Retrieved on: 
fredag, maj 3, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, American Academy, Dermatitis, Phase, LEO, Risk, Delgocitinib, Annual report, Leo Pharma, Tralokinumab, Growth, DKK, Affiliation, CHE, Patient, Acquisition, Psoriasis, AAD, Skin infection, Multimedia, Marketing, Atopic dermatitis, Ichthyosis, Pharmaceutical industry

In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).

Key Points: 
  • In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).
  • Dermatology revenue grew 16% to DKK 2,444 million (Q1 2023: 2,150 million), driven by growth of Adtralza®/Adbry® for atopic dermatitis (AD) and solid growth in the core portfolio.
  • “First quarter marks a solid start to 2024 with a 13% revenue growth and continued progress on our strategic priorities.
  • I am pleased with the strong growth track record for our global dermatology portfolio, primarily driven by performance in North America.

NEW AMERICAN ACADEMY OF DERMATOLOGY SURVEY: INCREASING NUMBER OF AMERICANS AT RISK OF SKIN CANCER DESPITE KNOWING HOW TO PROTECT THEMSELVES

Retrieved on: 
tisdag, april 30, 2024
UPF, American Academy, Cancer, Bleeding, Risk, FAAD, Skin, Burn, UVB, Health, Sunburn, Skin cancer, Tanning, Melanoma, Cheek, AAD, Eating, Diagnosis, SPF, UV, Clothing, Cosmetics

ROSEMONT, Ill., April 30, 2024 /PRNewswire/ -- Abby Weiner knew the dangers of unprotected sun exposure long before she was diagnosed with skin cancer. As someone with fair skin and freckles, the 43-year-old mother of three says she has always been diligent about wearing hats and using sunscreen when sitting at a beach or a pool but didn't think about the sun exposure she was getting elsewhere until she was diagnosed with melanoma on her cheek in 2023.

Key Points: 
  • The most avoidable risk factor for skin cancer, including melanoma—the deadliest type of skin cancer—is exposure to the sun.
  • In recognition of Skin Cancer Awareness Month in May and Melanoma Monday® on May 6, the American Academy of Dermatology (AAD) is encouraging the public to practice safe sun to reduce their risk of skin cancer.
  • "Data shows a staggering truth: one in five Americans will be diagnosed with some form of skin cancer in their lifetime.
  • To protect yourself from the sun and reduce your risk of skin cancer, the AAD recommends that everyone:
    Seek shade.

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
måndag, april 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
tisdag, april 16, 2024
SCI, FDA, Congress, American Academy, Investment, RAD, NDA, Insurance, Partnership, Research, Week, Patient, AAD, Atopic dermatitis, Arena Pharmaceuticals, Inflammation, Accounting, Annual general meeting, Asthma, Inflammatory Bowel Diseases, Type, Connect, UC, Pharmaceutical industry

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .

Key Points: 
  • Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .
  • Four posters at the 2023 World Congress of Dermatology in July 2023 on data from the initial 16-week treatment period with rademikibart of the pivotal trial in China in patients with moderate-to-severe AD.
  • Connect expects to receive an update from Simcere as early as Q2 2024 on these next steps.
  • Cash, cash equivalents and short-term investments were $118.7 million as of December 31, 2023, compared with $161.9 million on December 31, 2022.

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

Retrieved on: 
onsdag, april 10, 2024
FDA, Dexmedetomidine, Safety, Agitation, Food, Dementia, Intelligence, Live, Patient, AAD, Medicine, New product development, Database, Positive, Therapy, Type, Pharmaceutical industry

NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced details regarding the planned design of its upcoming TRANQUILITY In-Care Phase 3 trial to evaluate BXCL501, the company’s investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with Alzheimer’s dementia (AAD) in the care setting. The Company’s plan to conduct this trial is based on feedback received from the U.S. Food and Drug Administration (FDA), following the recent receipt of minutes from the Type B/Breakthrough Therapy designation meeting held with the agency on February 20, 2024.

Key Points: 
  • “The design of our upcoming TRANQUILITY In-Care trial largely mirrors TRANQUILITY II, which demonstrated positive efficacy and safety results with a 60 mcg dose of BXCL501,” said Vincent O’Neill, M.D., Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • “We have completed two recent meetings with the FDA on our TRANQUILITY program, and are pleased to have obtained clarity on the next steps for our AAD development path.
  • The trial is expected to enroll patients with episodic agitation, with patients self-administering 60 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.
  • A slide presentation on the TRANQUILITY program is available on the Investors section of the Company’s website: bioxceltherapeutics.com.